Clinical trialObsRecruiting
PAncreatic Disease Cohort of TOuLouse
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Recruiting
- Study type
- Observational
- Start
- 28 November 2023
- Expected end
- December 2027
- Enrollment
- 300 participants
- Sites
- 1
- Primary outcomes
- Diagnostic tools
- Sponsor
- Other
- Results posted
- No
- Last update
- 4 December 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.
Detailed description public domain (ClinicalTrials.gov)
This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.
Primary outcome public domain (ClinicalTrials.gov)
Diagnostic tools. To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies Time frame: 3 years after the first inclusion.
Secondary outcome public domain (ClinicalTrials.gov)
New targets. Time frame: 3 years after the first inclusion.
Secondary outcome public domain (ClinicalTrials.gov)
Improvement of management. Time frame: 3 years after the first inclusion.
Secondary outcome public domain (ClinicalTrials.gov)
Microbiota. Time frame: 3 years after the first inclusion.
Secondary outcome public domain (ClinicalTrials.gov)
Clinical data access. Time frame: 3 years after the first inclusion.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: * Patients with inflammatory or cystic exocrine pancreatic pathology * Patient able to read and understand the information leaflet * Patients who have agreed to participate in the study and have signed the free and informed consent * Patients affiliated to a social security system (including AME) Exclusion Criteria: * Patient with pancreatic cancer pathology * Patients with active cancer, whatever the origin * Pregnant or breastfeeding patients * Patients under legal protection, guardianship or trusteeship
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 300 participants (estimated).